Why Are Carisma Therapeutics Shares Surging Friday?
Why Are Carisma Therapeutics Shares Surging Friday?
Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.
Carisma Therapeutics Inc.(納斯達克股票代碼：CARM)的股價在週五上漲，因爲該公司宣佈與moderna合作的一項重大進展。
What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna.
了解詳情：Carisma已經推薦了其第一個針對Glypican-3(GPC3)的體內CAR-M研發候選物，用於治療實體瘤，包括肝細胞癌(HCC)。這個里程碑觸發了moderna向Carisma支付200萬美元的款項。
The development candidate leverages Carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages (CAR-M) with Moderna's mRNA and lipid nanoparticle platform. This collaboration aims to create novel in vivo cell therapies for oncology, with pre-clinical data showing promising results in redirecting myeloid cells to attack cancer cells directly in vivo.
這個研發候選物利用了Carisma在工程嵌合抗原受體單核細胞和巨噬細胞(CAR-M)方面的專業知識，結合了moderna的mRNA和脂質納米粒平台。這個合作旨在爲腫瘤學創造新的體內細胞治療方法，在臨床前數據中顯示，直接在體內重定向髓系細胞攻擊癌細胞的效果很有前途。
What Else: Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma, emphasized the significance of targeting GPC3, a highly expressed tumor antigen in HCC. Lin Guey, Chief Scientific Officer of Therapeutics Research Ventures at Moderna, expressed excitement about the progress and the potential for further development of CAR-M therapies for solid tumors.
還有什麼：Carisma的聯合創始人兼首席科學官Michael Klichinsky強調了有針對性地靶向GPC3在HCC中的高表達的腫瘤抗原的重要性。moderna治療研究風險首席科學官Lin Guey對CAR-M用於實體瘤治療的進展和進一步開發潛力表示興奮。
Additionally, HC Wainwright & Co. also reiterated a Buy rating on the stock, maintaining a price target of $8.
此外，HC Wainwright & Co.還重申了該股票的買入評級，並保持8美元的價格目標。
CARM Price Action: Carisma shares were up by 14.9% at $1.55 according to Benzinga Pro.
CARM股價走勢：根據Benzinga Pro的數據，Carisma股價上漲了14.9％，達到1.55美元。
Image: Steve Buissine from Pixabay.
圖片來源：Pixabay的Steve Buissine。
譯文內容由第三人軟體翻譯。